https://scholars.lib.ntu.edu.tw/handle/123456789/535261
標題: | Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis | 作者: | HSIN-YUN SUN Alexander B.D. Lortholary O. Dromer F. Forrest G.N. Lyon G.M. Somani J. Gupta K.L. Del Busto R. Pruett T.L. Sifri C.D. Limaye A.P. John G.T. Klintmalm G.B. Pursell K. Stosor V. Morris M.I. Dowdy L.A. Munoz P. Kalil A.C. Garcia-Diaz J. Orloff S. House A.A. Houston S. Wray D. Huprikar S. Johnson L.B. Humar A. Razonable R.R. Husain S. Singh N. |
公開日期: | 2009 | 出版社: | Oxford University Press | 卷: | 49 | 期: | 11 | 起(迄)頁: | 1721-1728 | 來源出版物: | Clinical Infectious Diseases | 摘要: | Background: Whether outcome of central nervous system (CNS) cryptococcosis in solid organ transplant recipients treated with lipid formulations of amphotericin B is different from the outcome of the condition treated with amphotericin B deoxycholate (AmBd) is not known. Methods: We performed a multicenter study involving a cohort comprising consecutive solid organ transplant recipients with CNS cryptococcosis. Results: Of 75 patients treated with polyenes as induction regimens, 55 (73.3%) received lipid formulations of amphotericin B and 20 (26.7%) received AmBd. Similar proportions of patients in both groups had renal failure at baseline ( P=.94). Overall, mortality at 90 days was 10.9% in the group that received lipid formulations of amphotericin B and 40.0% in the group that received AmBd. In univariate analysis, nonreceipt of calcineurin inhibitors (Pp.034), renal failure at baseline (P=.016), and fungemia (P=.003) were significantly associated with mortality. Compared with AmBd, lipid formulations of amphotericin B were associated with a lower mortality (P=.007). Mortality did not differ between patients receiving lipid formulations of amphotericin B with or without flucytosine (P=.349). In stepwise logistic regression analysis, renal failure at baseline (odds ratio [OR], 4.61; 95% confidence interval [CI], 1.02-20.80; P=.047) and fungemia (OR, 10.66; 95% CI, 2.08-54.55; P= .004) were associated with an increased mortality, whereas lipid formulations of amphotericin B were associated with a lower mortality (OR, 0.11; 95% CI, 0.02-0.57; Pp.008). Conclusions: Lipid formulations of amphotericin B were independently associated with better outcome and may be considered as the first-line treatment for CNS cryptococcosis in these patients. ? 2009 by the Infectious Diseases Society of America. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-72849130455&doi=10.1086%2f647948&partnerID=40&md5=9b3ade29bf6faa078ff038cfeaa3df36 https://scholars.lib.ntu.edu.tw/handle/123456789/535261 |
ISSN: | 1058-4838 | DOI: | 10.1086/647948 | SDG/關鍵字: | amphotericin B; amphotericin B deoxycholate; amphotericin B lipid complex; cyclosporin A; flucytosine; immunosuppressive agent; mycophenolic acid 2 morpholinoethyl ester; prednisone; tacrolimus; adult; article; central nervous system infection; cerebrospinal fluid culture; clinical trial; cohort analysis; controlled study; cryptococcosis; cytomegalovirus infection; drug efficacy; drug formulation; female; fungemia; graft rejection; heart transplantation; human; immunosuppressive treatment; kidney failure; kidney transplantation; liver transplantation; logistic regression analysis; lung transplantation; major clinical study; male; mortality; multicenter study; organ transplantation; pancreas transplantation; priority journal; risk assessment; treatment outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。